These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18604455)

  • 21. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
    Kennedy P
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S3-13. PubMed ID: 24217189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccination and multiple sclerosis].
    Löbermann M; Winkelmann A; Reisinger EC; Zettl UK
    Nervenarzt; 2010 Feb; 81(2):181-93. PubMed ID: 19838662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Copolymer 1 from the laboratory to FDA.
    Teitelbaum D; Sela M; Arnon R
    Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880
    [No Abstract]   [Full Text] [Related]  

  • 26. Multiple sclerosis: new insights in pathogenesis and novel therapeutics.
    Ontaneda D; Hyland M; Cohen JA
    Annu Rev Med; 2012; 63():389-404. PubMed ID: 21888515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory treatment strategies in multiple sclerosis.
    Kieseier BC; Wiendl H; Leussink VI; Stüve O
    J Neurol; 2008 Dec; 255 Suppl 6():15-21. PubMed ID: 19300955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties.
    Jafarzadeh A; Nemati M
    J Neuroimmunol; 2018 Nov; 324():54-75. PubMed ID: 30243185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple sclerosis: a review of existing therapy and future prospects.
    Khan OA
    J Pak Med Assoc; 1996 Jan; 46(1):20-4. PubMed ID: 8830165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines and disease-modifying treatments.
    Waubant E; Giovannoni G; Hawkes C; Levy M
    Mult Scler Relat Disord; 2018 Nov; 26():A1-A2. PubMed ID: 30573174
    [No Abstract]   [Full Text] [Related]  

  • 31. Effector and regulatory B cells in Multiple Sclerosis.
    Staun-Ram E; Miller A
    Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.
    Tumani H; Uttner I
    J Neurol; 2007 May; 254 Suppl 2():II69-72. PubMed ID: 17503133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drug therapies for multiple sclerosis.
    Mangas A; Coveñas R; Geffard M
    Curr Opin Neurol; 2010 Jun; 23(3):287-92. PubMed ID: 20414110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis.
    Marques VD; Passos GRD; Mendes MF; Callegaro D; Lana-Peixoto MA; Comini-Frota ER; Vasconcelos CCF; Sato DK; Ferreira MLB; Parolin MKF; Damasceno A; Grzesiuk AK; Muniz A; Matta APDC; Oliveira BES; Tauil CB; Maciel DRK; Diniz DS; Corrêa EC; Coronetti F; Jorge FMH; Sato HK; Gonçalves MVM; Sousa NAC; Nascimento OJM; Gama PDD; Domingues R; Simm RF; Thomaz RB; Morales RR; Dias RM; Apóstolos-Pereira SD; Machado SCN; Junqueira TF; Becker J
    Arq Neuropsiquiatr; 2018 Aug; 76(8):539-554. PubMed ID: 30231128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New therapeutic approaches for multiple sclerosis.
    De Jager PL; Hafler DA
    Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.